What Have We Learned About the Treatment of Type 2 Diabetes? The Evolving Paradigms

被引:2
作者
Freeman, Jeffrey S. [1 ]
Horton, Edward S. [2 ]
机构
[1] Philadelphia Coll Osteopath Med, Div Endocrinol & Metab, Philadelphia, PA 19131 USA
[2] Joslin Diabet Ctr, Boston, MA 02215 USA
关键词
type; 2; diabetes; management; efficacy; safety; ADD-ON THERAPY; INADEQUATE GLYCEMIC CONTROL; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; IMPAIRED GLUCOSE-TOLERANCE; PROTAMINE HAGEDORN INSULIN; INCRETIN-BASED THERAPIES; TWICE-DAILY EXENATIDE; TO-TARGET TRIAL; BASAL INSULIN; DOUBLE-BLIND;
D O I
10.1097/MJT.0b013e31826fc5e5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Insulin, the first treatment for diabetes, was discovered >90 years ago. Since then, many new types of insulin have become available, including analogs that more closely mimic the characteristics of endogenous insulin. In addition, oral antidiabetes drugs and other types of injectable therapies have been approved for the treatment of patients with type 2 diabetes. As newer treatments are approved for type 2 diabetes, the choice and-paradoxically-the complexity of treatment increases. The potential benefits of all treatment options must be carefully balanced against potential adverse events to truly analyze the overall efficacy, safety, tolerability, and potential long-term effects. The manner in which outcomes are assessed and the methods employed to make such assessments have changed over time. This review will address these issues as they are related to therapies for type 2 diabetes, including insulin, oral antidiabetes drugs, and incretin-based agents.
引用
收藏
页码:449 / 464
页数:16
相关论文
共 50 条
  • [31] Endometriosis and Reproduction: What We Have Learned
    Garcia-Fernandez, Jaime
    Garcia-Velasco, Juan A.
    YALE JOURNAL OF BIOLOGY AND MEDICINE, 2020, 93 (04) : 571 - 577
  • [32] Revealed versus Stated Preferences: What Have We Learned About Valuation and Behavior?
    Alberini, Anna
    REVIEW OF ENVIRONMENTAL ECONOMICS AND POLICY, 2019, 13 (02) : 283 - 298
  • [33] Peripheral spondyloarthritis: What have we learned?
    Puche-Larrubia, Maria Angeles
    Lopez-Medina, Clementina
    Ziade, Nelly
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2023, 37 (03):
  • [34] What have we learned from BeSt?
    Allaart, Cornelia F.
    Markusse, Iris M.
    Lems, Willem F.
    CLINICAL IMMUNOLOGY, 2018, 186 : 74 - 78
  • [35] A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
    Liu, Christine
    Kieltyka, Jacqueline
    Fleischmann, Roy
    Gadina, Massimo
    O'Shea, John J.
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (12) : 2166 - 2178
  • [36] Residual macrovascular risk in 2013: what have we learned?
    Fruchart, Jean-Charles
    Davignon, Jean
    Hermans, Michel P.
    Al-Rubeaan, Khalid
    Amarenco, Pierre
    Assmann, Gerd
    Barter, Philip
    Betteridge, John
    Bruckert, Eric
    Cuevas, Ada
    Farnier, Michel
    Ferrannini, Ele
    Fioretto, Paola
    Genest, Jacques
    Ginsberg, Henry N.
    Gotto, Antonio M., Jr.
    Hu, Dayi
    Kadowaki, Takashi
    Kodama, Tatsuhiko
    Krempf, Michel
    Matsuzawa, Yuji
    Nunez-Cortes, Jesus Millan
    Monfil, Carlos Calvo
    Ogawa, Hisao
    Plutzky, Jorge
    Rader, Daniel J.
    Sadikot, Shaukat
    Santos, Raul D.
    Shlyakhto, Evgeny
    Sritara, Piyamitr
    Sy, Rody
    Tall, Alan
    Tan, Chee Eng
    Tokgozoglu, Lale
    Toth, Peter P.
    Valensi, Paul
    Wanner, Christoph
    Zambon, Alberto
    Zhu, Junren
    Zimmet, Paul
    CARDIOVASCULAR DIABETOLOGY, 2014, 13
  • [37] Cryoablation for Atrial Fibrillation in 2017: What Have We Learned?
    Shakkottai, Padmanabhan
    Sy, Raymond W.
    McGuire, Mark A.
    HEART LUNG AND CIRCULATION, 2017, 26 (09) : 950 - 959
  • [38] Service operations: what have we learned?
    Victorino, Liana
    Field, Joy M.
    Buell, Ryan W.
    Dixon, Michael J.
    Goldstein, Susan Meyer
    Menor, Larry J.
    Pullman, Madeleine E.
    Roth, Aleda V.
    Secchi, Enrico
    Zhang, Jie J.
    JOURNAL OF SERVICE MANAGEMENT, 2018, 29 (01) : 39 - 54
  • [39] Evolving Concepts of Type 2 Diabetes Management
    Abushamat, Layla A.
    Reusch, Jane E. B.
    MEDICAL CLINICS OF NORTH AMERICA, 2021, 105 (06) : 955 - 966
  • [40] Type 2 diabetes: Evolving concepts and treatment
    Miller, Eden
    Aguilar, Richard B.
    Herman, Mary E.
    Schwartz, Stanley S.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2019, 86 (07) : 494 - 504